“R.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
Samples taken from patients with initial COVID-19 outbreaks in China were effectively analysed
SAN DIEGO, 6 August 2020 (GLOBE NEWSWIRE) – Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that significant progress has been made in the past announced genetic studies of COVID-19 hosts on the initial outbreaks of COVID-19 in Wuhan and Shanghai, and that researchers have effectively analyzed Bionano Saphyr patient samples at the Wuhan-based service provider’s site , GrandOmics. These studies aim to compare a variety of genomic and biological variables between patients who have no mild symptoms or symptoms and those with a serious disease, while controlling differences in viral strains and known threat points for age and chronic diseases such as asthma. diabetes or other immune disease.
Studies in Wuhan and Shanghai had suffered setbacks due to institutional and governmental restrictions on genomic DNA research of COVID-19 patients for these host genome studies, and additional restrictions on sending patient samples to remedy delayed progress in those studies. . These barriers have now been removed and the first 4 coVID-19 patient samples from the Shanghai cohort have been effectively treated, generating exceptional measurements of the quality of knowledge and DNA. Samples from the Wuhan cohort are also known and are waiting to be repaired.
Bionano Genomics hopes that its saphyr genome imaging can provide the vital knowledge of structural variation needed for a comprehensive understanding of genome design in COVID-19 patients. As announced in the past on July 24, 2020, the unreleased initial effects of 30 COVID-19 patients analyzed in Saphyr as a component of the COVID-19 Host Genome Variation Consortium show that Saphyr detects giant amounts of structural variation in many supposedly applicable genes, demonstrating that point mutations alone are most likely not disease differences between patients.
Erik Holmlin, PhD, CEO of Bionano Genomics commented: “We believe that the paintings of these studies may be essential for the progression of new therapies, vaccines and diagnoses designed to improve the control of patients with COVID-19. While studies in Europe and North America focused on COVID-19 Host Genome Structural Variation Consortium are underway, we are pleased that studies on the host genome of the initial epidemic in China are also progressing. We are proud of our team and our painters who have triumphed over significant obstacles to make this progress.
About Bionano Genomics Bionano is a genome study company that supplies equipment and relies on its Saphyr formula for scientists and physicians conducting genetic studies and patient testing. Bionano’s Saphyr system is an ultra-sensitive and ultra-specific structural variation detection platform that allows scholars and physicians to drive the search for new cure diagnoses and objectives and expedite the examination of chromosomal changes, called cytogenetics. Saphyr’s formula consists of an instrument, chip consumables, reagents and a set of knowledge studies and genome studies teams to provide access to Saphyr’s knowledge to scholars who prefer not to adopt the Saphyr formula in their laboratories. For more information, scale www.bionanogenomics.com.
Forward-Looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “possibly,” “goes,” “anticipate,” “plan,” “anticipate,” “estimate,” “intention, ” and similar expressions (as well as other words or words that refer to long-term occasions, situations, or circumstances) express the uncertainty of long-term occasions or effects and are intended to identify such forward-term statements. Forward-looking statements come with statements relating to our existing intentions, beliefs, projections, perspectives, analyses or expectations related, inter alia, to the progress of studies involving our genome imaging; expectations about the usefulness of Saphyr genome imaging in COVID-19 studies; and the effects of studies involving our genome imaging, adding COVID-19 studies and the progression of possible remedies for COVID-19 patients. Each of these forward-looking statements carries dangers and uncertainties. Actual effects or progressions may differ materially from those projected or implied in such forward-looking statements. The factors that would possibly cause such a difference come with the related dangers and uncertainties: delays in studies and other study activities involving our generation, adding institutional, governmental and other constraints; have an effect on the COVID-19 pandemic on our business and the global economy; General market situations Changes in the competitive landscape and the advent of competitive products; Changes in our strategic and business plans, our ability to make investments safe enough to finance our strategic plans and marketing efforts; Loss of key members of the control and sales team; and the dangers and uncertainties associated with our overall trading and monetary position, adding the dangers and uncertainties described in our filings to the Securities and Exchange Commission, adding, but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2019 and other documents that we subsequently filed with the Securities and Exchange Commission. All forward-looking statements contained in this press release relate only to the date on which they were made and are based on the control assumptions and estimates to that date. We disclaim any legal responsibility to publicly update any forward-looking statements, whether as a result of receiving new information, long-term or otherwise occasions.
Company contact: Erik Holmlin, CEO of Bionano Genomics, Inc. -1 (858) 888-7610 [email protected]
Investor Relations Contact: Ashley R. Robinson LifeSci Advisors, LLC (617) 430-7577 [email protected]
Press contact: Kirsten Thomas The Ruth Group (508) 280-6592 [email protected]